Q1 2026 Kura Oncology Inc Earnings Call Transcript
Key Points
- Kura Oncology Inc (KURA) reported $5.8 million in net product revenue from the first full quarter of KOMZIFTI's launch, exceeding expectations.
- The company is seeing strong physician adoption with repeat prescriptions and increasing use across treatment centers.
- KOMZIFTI is gaining traction as a differentiated product due to its compelling efficacy, predictable safety profile, and convenient dosing.
- Kura Oncology Inc (KURA) has a robust pipeline with multiple anticipated near-term clinical catalysts, including data readouts for ziftomenib and darlifarnib.
- The company has secured coverage at parity or better for more than 93% of covered lives, reflecting strong payer recognition of KOMZIFTI's value.
- Kura Oncology Inc (KURA) reported a net loss of $73.3 million for the first quarter of 2026, compared to a net loss of $57.4 million for the same period in 2025.
- Research and development expenses increased to $65.3 million, driven by ziftomenib combination trials.
- Selling, general, and administrative expenses rose to $31.6 million due to the commercial launch of KOMZIFTI.
- The company's cash equivalents and short-term investments decreased from $667.2 million at the end of 2025 to $580.8 million as of March 31, 2026.
- There is uncertainty regarding the duration of treatment with KOMZIFTI, as the company needs more time to track patient data over several quarters.
Good day, everyone. My name is Leila, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology first quarter 2026 financial results earnings call. (Operator Instructions)
At this time, I would like to turn the call over to Greg Mann, SVP of Investor Relations and Corporate Affairs of Kura Oncology. Please go ahead.
Thank you, Leila. Good afternoon and welcome to Kura Oncology's first quarter 2026 conference call. Joining the call today are Dr. Troy Wilson, President and Chief Executive Officer; Brian Powl, Chief Commercial Officer; Dr. Mollie Leoni, Chief Medical Officer; and Tom Doyle, Senior Vice President, Finance and Accounting.
We remind you that today's discussion will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that cause actual results to differ materially from expected results.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
